Pembrolizumab (formerly lambrolizumab, trade name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer. Other names: MK-3475, lambrolizumab
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of pembrolizumab brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 / 9891296838 or Email Us to know more details about the medicine and its cost price in India.
The order for pembrolizumab will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
KEYTRUDA® (pembrolizumab) injection, for intravenous use. Initial U.S. Approval: 2014
Generic Name: pembrolizumab
For injection: 50 mg lyophilized powder in single-dose vial for reconstitution.
Injection: 100 mg/4 mL (25 mg/mL) solution in a single-dose vial
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand pembrolizumab on prescription and Import License in Patient's Name only.
For overseas patients, pembrolizumab can be made available in Send your enquiry to find pembrolizumab in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For KEYTRUDA® (pembrolizumab) Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
Learn more I agree European Commission Approves Two New Regimens of Merck’s KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) For More Details
EU approval for Keytruda in head and neck cancer For More Details
Lenvatinib/Pembrolizumab Combo Demonstrates Strong Antitumor Activity in Metastatic RCC For More Details